Results 11 to 20 of about 27,891 (280)

A systematic review and meta-analysis of loratadine combined with montelukast for the treatment of allergic rhinitis

Frontiers in Pharmacology, 2023
Background: Loratadine and montelukast are clinical first-line drugs in the treatment of allergic rhinitis (AR). However, there is no clear evidence of the efficacy of loratadine combined with montelukast in the treatment of AR.
Huan Wang, Huan Wang, Qing Ji, Chao Liao, Li Tian   +4 more
doaj   +2 more sources

Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review

European Respiratory Review, 2023
Background: The United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk of developing specific neuropsychiatric events in montelukast users remain ...
Chris Wai Hang Lo, Swathi Pathadka, Simon Xiwen Qin, Lydia W.Y. Fung, Vincent Ka Chun Yan, Hei Hang Edmund Yiu, Chloe I. Bloom, Ian Chi Kei Wong, Esther Wai Yin Chan   +8 more
doaj   +2 more sources

Effects of Montelukast on Arsenic-Induced Epithelial-Mesenchymal Transition and the Role of Reactive Oxygen Species Production in Human Bronchial Epithelial Cells

Frontiers in Pharmacology, 2022
Background: Epithelial-mesenchymal transition (EMT) of airway lung epithelial cells is considered a major driver of fibrosis and airway remodeling. Arsenic exposure is well known to cause the malignant transformation of cells, including those in the lung.
Huang-Chi Chen, Huang-Chi Chen, Hsin-Ying Clair Chiou, Hsin-Ying Clair Chiou, Mei-Lan Tsai, Mei-Lan Tsai, Szu-Chia Chen, Szu-Chia Chen, Szu-Chia Chen, Ming-Hong Lin, Ming-Hong Lin, Ming-Hong Lin, Ming-Hong Lin, Tzu-Chun Chuang, Chih-Hsing Hung, Chih-Hsing Hung, Chih-Hsing Hung, Chih-Hsing Hung, Chao-Hung Kuo, Chao-Hung Kuo, Chao-Hung Kuo   +20 more
doaj   +2 more sources

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network

Frontiers in Pharmacology, 2021
Montelukast is a selective leukotriene receptor antagonist that is widely used to treat bronchial asthma and nasal allergy. To clarify the association between montelukast and neuropsychiatric adverse events (AEs), we evaluated case reports recorded ...
Ryogo Umetsu, Mizuki Tanaka, Yoko Nakayama, Yamato Kato, Natsumi Ueda, Yuri Nishibata, Shiori Hasegawa, Kiyoka Matsumoto, Noriaki Takeyama, Kazuhiro Iguchi, Hiroyuki Tanaka, Eiichi Hinoi, Eiichi Hinoi, Naoki Inagaki, Masatoshi Inden, Yoshinori Muto, Mitsuhiro Nakamura   +16 more
doaj   +2 more sources

The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-KATP channels pathway

Frontiers in Pharmacology, 2022
Inflammatory bowel disease is a chronic autoimmune disorder that may involve entire gastrointestinal tract. The leukotrienes have a role as mediators in the pathophysiology of colitis. Here, we investigated the effect of a leukotriene receptor antagonist,
Behnam Ghorbanzadeh, Mohammad Amin Behmanesh, Roya Mahmoudinejad, Mehdi Zamaniyan, Shadi Ekhtiar, Yousef Paridar   +5 more
doaj   +2 more sources

Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity

Journal of Neuroinflammation, 2022
Encephalopathy of prematurity (EoP) affects approximately 30% of infants born
Abi G. Yates, Elena Kislitsyna, Carla Alfonso Martin, Jiaying Zhang, Amy L. Sewell, Ane Goikolea-Vives, Valerie Cai, Lama F. Alkhader, Aleksander Skaland, Basil Hammond, Ralica Dimitrova, Dafnis Batalle, Cathy Fernandes, A. David Edwards, Pierre Gressens, Claire Thornton, Helen B. Stolp   +16 more
doaj   +2 more sources

Montelukast use over the past 20 years: monitoring of its effects and safety issues [PDF]

Clinical and Experimental Pediatrics, 2020
Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (
Yong Ju Lee, Chang-Keun Kim
doaj   +2 more sources

Phase 2 trial of montelukast for prevention of pain in sickle cell disease. [PDF]

Blood Advances, 2020
Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle cell disease (SCD), levels of CysLTs are increased compared with controls and associated with a higher rate of hospitalization for pain. We tested the hypothesis
Brandow, Amanda, Bryant, Valencia, DeBaun, Michael R, Embury, Stephen H, Field, Joshua J, Kassim, Adetola, Matsui, Neil, Simpson, Pippa, Wilkerson, Karina, Zhang, Liyun   +9 more
core   +2 more sources

LTA4H rs2660845 association with montelukast response in early and late-onset asthma.

PLoS ONE, 2021
Leukotrienes play a central pathophysiological role in both paediatric and adult asthma. However, 35% to 78% of asthmatics do not respond to leukotriene inhibitors.
Cyrielle Maroteau, Antonio Espuela-Ortiz, Esther Herrera-Luis, Sundararajan Srinivasan, Fiona Carr, Roger Tavendale, Karen Wilson, Natalia Hernandez-Pacheco, James D Chalmers, Steve Turner, Somnath Mukhopadhyay, Anke-Hilse Maitland-van der Zee, Esteban G Burchard, Maria Pino-Yanes, Simon Young, Glenda Lassi, Adam Platt, Colin N A Palmer, PiCA Consortium   +18 more
doaj   +2 more sources

Montelukast Use Decreases Cardiovascular Events in Asthmatics

Frontiers in Pharmacology, 2021
Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology.
Malvina Hoxha, Malvina Hoxha, Calogero C. Tedesco, Silvana Quaglin, Visar Malaj, Linda Pustina, Valerie Capra, Jilly F. Evans, Angelo Sala, Angelo Sala, G. Enrico Rovati   +10 more
doaj   +2 more sources